Literature DB >> 19194879

Immunoglobulins and complement in postmortem multiple sclerosis tissue.

Michael H Barnett1, John D E Parratt, Eun-Sook Cho, John W Prineas.   

Abstract

OBJECTIVE: To identify evidence of a discrete, specific immune response in multiple sclerosis (MS) by analyzing the distribution of immunoglobulins and complement in tissue derived from cases of MS, and from control inflammatory white matter diseases known to express viral and autoantigens in the brain and spinal cord.
METHODS: Autopsy tissue from 25 MS patients and 24 patients with other neurological diseases was examined immunohistochemically for immunoglobulins and activated complement (C3d and C9neo).
RESULTS: In tissue remote from focal lesions in MS and other neurological diseases, IgG was detected in many normal structures but not in myelin or ramified microglia. Disrupted myelin in areas of active myelin breakdown and in phagocytes stained positively for C3d and C9neo, and equivocally for IgG in MS and all other neurological diseases examined, including ischemic infarcts. Disease-specific deposits of IgG or complement were detected in virus-infected cells in progressive multifocal leukoencephalopathy, subacute sclerosing panencephalitis, and cytomegalovirus encephalitis; in glial-limiting membranes in neuromyelitis optica; and in senile plaques in Alzheimer's dementia. Specific to MS were unusual microglial nodules containing short, linear deposits of activated complement (C3d) on partly demyelinated axons located in normal-appearing periplaque white matter.
INTERPRETATION: IgG and complement immunostaining of disrupted myelin in MS lesions, frequently cited as an indication of pathogenic anti-myelin antibodies, is a nonspecific feature that cannot be interpreted as evidence of a distinct pathogenesis or serve to define particular variants of the disease. The unusual microglial nodules described in this study may constitute a specific biomarker with pathogenetic significance in MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194879     DOI: 10.1002/ana.21524

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  56 in total

1.  Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma.

Authors:  Alejandra Bosco; Sarah R Anderson; Kevin T Breen; Cesar O Romero; Michael R Steele; Vince A Chiodo; Sanford L Boye; William W Hauswirth; Stephen Tomlinson; Monica L Vetter
Journal:  Mol Ther       Date:  2018-08-24       Impact factor: 11.454

Review 2.  Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury.

Authors:  Tobias Derfuss; Chris Linington; Reinhard Hohlfeld; Edgar Meinl
Journal:  J Mol Med (Berl)       Date:  2010-05-06       Impact factor: 4.599

Review 3.  B cells in multiple sclerosis: connecting the dots.

Authors:  H-Christian von Büdingen; Amit Bar-Or; Scott S Zamvil
Journal:  Curr Opin Immunol       Date:  2011-10-07       Impact factor: 7.486

4.  Altered hippocampal GABA and glutamate levels and uncoupling from functional connectivity in multiple sclerosis.

Authors:  Fei Gao; Xuntao Yin; Richard A E Edden; Alan C Evans; Junhai Xu; Guanmei Cao; Honghao Li; Muwei Li; Bin Zhao; Jian Wang; Guangbin Wang
Journal:  Hippocampus       Date:  2018-11       Impact factor: 3.899

5.  C3-dependent mechanism of microglial priming relevant to multiple sclerosis.

Authors:  Valeria Ramaglia; Timothy R Hughes; Rossen M Donev; Marieta M Ruseva; Xiaobo Wu; Inge Huitinga; Frank Baas; James W Neal; B Paul Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 6.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

Review 7.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

8.  Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis.

Authors:  Athena M Soulika; Eunyoung Lee; Erica McCauley; Laird Miers; Peter Bannerman; David Pleasure
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

Review 9.  Encephalitis and epilepsy.

Authors:  Jan Bauer; Christian G Bien
Journal:  Semin Immunopathol       Date:  2009-09-11       Impact factor: 9.623

10.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.